Overexpression, effective renaturation, and bioactivity of novel single-chain antibodies against TNF-α

Preparative Biochemistry and Biotechnology

Volumn 38, Issue 1, 2008, Pages 74-86

  Geng, Shusheng ^a,b   Chang, Hong ^b   Qin, Weisong ^c   Li, Yan ^b   Feng, Jiannan ^b   Shen, Beifen ^b  

^a HEBEI UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

Antagonistic peptide; Cytotoxicity; Inclusion body; Refolding; Single chain antibody; Tumor necrosis factor

Indexed keywords

ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNE DISEASE; CELL LINE; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN RENATURATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN RENATURATION; TUMOR NECROSIS FACTOR-ALPHA;

ESCHERICHIA COLI;

EID: 37249088464     PISSN: 10826068     EISSN: 15322297     Source Type: Journal    
DOI: 10.1080/10826060701774379     Document Type: Article

References (26)

1. Kazuhiro, N.; Yoshiaki, F.; Takaaki, N.; Hiroshi, K.; Chika, N.; Tatsuya, K.; Shinzo, O.; Toshihiro, N. Construction and expression of a mouse-human chimeric antibody against human tumor necrosis factor-α. Immunol. Lett. 1998, 64, 139-144.
2. Beutler, B.; Cerami, A. The biology of cachetin/TNF. A primary mediator of the host response. Ann. Rev. Immunol. 1989, 7, 625-655.
3. Kollias, G.; Douni, E.; Kassiotis, G.; Kontoyiannis, D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. 1999, 169, 175-194.
4. Fabiola, A.; Piercarlo, S.P.; Andrea, D.; Luca, I.; Franco, C. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 2005, 4, 144-152.
5. Taylor, P.C. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol. Biotechnol. 2001, 19, 153-168.
6. Wolf, R.; Matz, H.; Orion, E.; Ruocco, V. Anti-TNF therapies-the hope of tomorrow. Clin. Dermatol. 2002, 20, 522-530.
7. Palladino, M.A.; Bahjat, F.R.; Theodorakis, E.A.; Moldawer, L.L. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Disc. 2003, 2, 736-746.
8. Moreland, L.W.; Baumgartner, S.W.; Schiff, M.H.; Tindall, E.A.; Fleischmann, R.M.; Weaver, A.L.; Ettlinger, R.E. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997, 337, 141-147.
9. Maini, R.; St. Clair, E.W.; Breedveld, F.; Furst, D.; Kalden, J.; Weisman, M.; Smolen, J. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999, 354, 1932-1939.
10. Leonardi, C.L.; Powers, J.L.; Matheson, R.T.; Goffe, B.S.; Zitnik, R.; Wang, A.; Gottlieb, A.B. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 2003, 349, 2014-2022.
11. Feldmann, M.; Maini, R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol. 2001, 19, 163-196.
12. Keane, J.; Gershon, S.; Wise, R.P.; Mirabile-Levens, E.; Kasznica, J.; Schwieterman, W.D.; Siegel, J.N.; Braun, M.M. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N. Engl. J. Med. 2001, 345, 1098-1104.
13. Holliger, P.; Hudson, P. Engineered antibody fragments and the rise of single domains. Nature Biotechnol. 2005, 23, 1126-1136.
14. Wörn, A.; Plückthun, A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 2001, 305, 989-1010.
15. Verma, R.; Boleti, E.; George, A.J.T. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Meth. 1998, 216, 165-181.
16. Knappik, A.; Ge, L.; Honegger, A.; Pack, P.; Fischer, M.; Wellnhofer, G.; Hoess, A. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 2000, 296, 57-86.
17. Zhang, W.; Feng, J.N.; Shen, B.F. Identification of binding epitope of a monoclonal antibody (Z12) against human TNF-alpha using computer modeling and deletion mutant technique. Sci. China C. Life Sci. 2004, 47, 279-286.
18. Feng, J.N.; Li, Y.; Zhang, W.; Shen, B.F. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. Immunol. Lett. 2005, 98, 311-316.
19. Qin, W.S.; Feng, J.N.; Li, Y.; Lin, Z.; Shen, B.F. De novo design TNF- aantagonistic peptide based on the complex structure of TNF-α with its neutralizing monoclonal antibody Z12. J. Biotechnol. 2006, 125, 57-63.
20. Qin, W.S.; Feng, J.N.; Li, Y.; Lin, Z.; Shen, B.F. A novel domain antibody rationally designed against TNF-α using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides. Mol. Immunol. 2007, 44, 2355-2361.
21. Qin, W.S.; Feng, J.N.; Li, Y.; Lin, Z.; Shen, B.F. Fusion protein of CDR mimetic peptide with Fc inhibit TNF-α induced cytotoxicity. Mol. Immunol. 2006, 43, 660-666.
22. Wan, L.; Zeng, L.Y.; Chen, L.H.; Huang, Q.; Li, S.F.; Lu, Y.R.; Li, Y.P. Expression, purification, and refolding of a novel immunotoxin containing humanized single-chain fragment variable antibody against CTLA4 and the N-terminal fragment of human perforin. Protein Expr. Purif. 2006, 48, 307-313.
23. Arakawa, T.; Kita, Y. Protection of bovine serum albumin from aggregation by Tween 80. J. Pharm. Sci. 2000, 89, 646-651.
24. Kim, B.D.; Na, K.; Choi, H.K. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur. J. Pharm. Sci. 2005, 24, 199-205.
25. Márquez-Velasco, R.; Bojalil, R.; Buelna, A.; Flores- Guzmán, F.; Estevez-Ramirez, J.; Laguna, J.; Hernández, A.M. Anti-tumor necrosis factor a F(ab′)2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome. Inflamm. Res. 2006, 55, 378-384.
26. Junming, L.; Jan, V.; Peter, D.; John, G.; David, K.; Scott, S. Anti-TNF antibodies and peptides of human necrosis factor. U. S. Patent 6790444, 2004, 9, 14.